Gilead Sciences Inc (GILD) Stock Price, Quote & News

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 574 3000

Fax: 650 578 9264

Website: www.gilead.com

Address:

333 Lakeside Drive, Foster City, United States

HedgeAlerts Nov. 16 at 10:22 PM

Hedge Alert Live - Protect Your Portfolio Contract: $GILD $125.00 Put · NOV 21, 2025 Exp Entry Price: $1.88 - $2.03 Exit Price Target: $2.90 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Dachshundtrader Nov. 16 at 8:35 AM

$ASMB $GILD

0 · Reply

WayneSmith Nov. 16 at 2:02 AM

$GILD $PANW $PFE $DHR Buy low and sell high

0 · Reply

HedgeAlerts Nov. 15 at 10:25 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 5:07 PM

💎 LiquidTheta® Live Actionable Trade Asset: $GILD Contracts: $GILD December 18, 2026 $150 Calls Scale in: $5.61- $6.86 Scale out: $21.81-$37.39 Profit Potential : 94% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

TechTraderGrok Nov. 14 at 9:08 PM

Bought $GILD at $124.96. From Grok: "GILD is in a clear uptrend with EMA above SMA, price above both and rising, recent breakout above 124 resistance on high volume, supported by positive oncology pipeline momentum and no near-term earnings risk, targeting next resistance near 130 over the next few weeks; re-entering soon after 11/12 exit as price surpassed prior resistance with strong momentum, invalidating overbought concerns, and no ongoing bearish factors." https://www.techtrader.ai/grokwall/?post=15542&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

GorillaTrades Nov. 14 at 8:20 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Frontline $FRO +7.7%, Gilead Sciences $GILD +5.1%, and Steel Dynamics $STLD +2.8%

0 · Reply

HedgeAlerts Nov. 14 at 6:08 PM

Hedge Alert Live - Protect Your Portfolio Contract: $GILD $124.00 Put · NOV 21, 2025 Exp Entry Price: $2.10 - $2.78 Exit Price Target: $4.14 Profit Margin: +49% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

GettnFibbywIT Nov. 14 at 5:03 PM

$GILD $XLV $IBB GILD - Pulled back with broader market, let's see if we can hold below level(s)........

0 · Reply

LiquidThetaOptions Nov. 14 at 4:31 PM

💎 LiquidTheta® Live Actionable Trade Asset: $GILD Contracts: $GILD December 18, 2026 $150 Calls Scale in: $5.59- $6.83 Scale out: $21.73-$37.25 Profit Potential : 314% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Nov 13, 2025, 9:00 AM EST - 3 days ago

Can Gilead Stock Outrun Regeneron In The Next Rally?

Nov 13, 2025, 8:30 AM EST - 3 days ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Nov 10, 2025, 2:41 PM EST - 6 days ago

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:00 AM EST - 6 days ago

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Nov 7, 2025, 8:41 AM EST - 9 days ago

Gilead's breast cancer drug fails to meet main goal of late-stage study

Nov 7, 2025, 8:30 AM EST - 9 days ago

Gilead Provides Update on Phase 3 ASCENT-07 Study

Nov 7, 2025, 8:00 AM EST - 9 days ago

Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

Nov 4, 2025, 4:05 PM EST - 12 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

Nov 3, 2025, 9:10 AM EST - 13 days ago

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Oct 31, 2025, 1:41 PM EDT - 16 days ago

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Oct 31, 2025, 8:00 AM EDT - 16 days ago

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Oct 30, 2025, 8:56 PM EDT - 16 days ago

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:05 PM EDT - 17 days ago

Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Oct 30, 2025, 4:02 PM EDT - 17 days ago

Gilead Sciences Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:11 PM EDT - 18 days ago

Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes

Oct 28, 2025, 10:40 AM EDT - 19 days ago

Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings

ABBV LLY MRK

Oct 24, 2025, 10:56 AM EDT - 23 days ago

What To Expect From Gilead In Q3 2025

Oct 23, 2025, 8:00 AM EDT - 24 days ago

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

Oct 21, 2025, 6:21 PM EDT - 26 days ago

Final Trade: F, HAL, MA, GILD

F HAL MA

Oct 21, 2025, 6:30 AM EDT - 26 days ago

AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

Oct 19, 2025, 8:30 AM EDT - 4 weeks ago

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Oct 19, 2025, 2:33 AM EDT - 4 weeks ago

Gilead's Trodelvy cuts breast cancer risk by 38% in trial

Oct 19, 2025, 2:30 AM EDT - 4 weeks ago

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

Oct 18, 2025, 10:00 PM EDT - 4 weeks ago

Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

Oct 15, 2025, 3:30 AM EDT - 4 weeks ago

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Oct 13, 2025, 10:33 AM EDT - 4 weeks ago

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Oct 13, 2025, 8:30 AM EDT - 4 weeks ago

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

Oct 10, 2025, 1:44 PM EDT - 5 weeks ago

Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase

COIN PANW RKLB

Oct 9, 2025, 4:05 PM EDT - 5 weeks ago

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Sep 30, 2025, 12:55 PM EDT - 6 weeks ago

Dividend Shields: Top 5 Income Stocks

ALEX LTC OMF THG

Sep 29, 2025, 5:45 AM EDT - 6 weeks ago

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

Sep 26, 2025, 1:47 PM EDT - 7 weeks ago

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

ABBV AMGN LLY MRK MRNA PFE

Sep 25, 2025, 8:00 AM EDT - 7 weeks ago

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

Sep 23, 2025, 6:45 PM EDT - 7 weeks ago

Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More

Sep 17, 2025, 9:16 PM EDT - 2 months ago

Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management

Sep 10, 2025, 1:38 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 9, 2025, 2:16 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 4, 2025, 2:15 PM EDT - 2 months ago

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Sep 4, 2025, 2:13 PM EDT - 2 months ago

US plans to bring Gilead HIV drug to market in high-burden HIV countries

Sep 4, 2025, 2:00 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 8:30 AM EDT - 2 months ago

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

Sep 3, 2025, 2:30 PM EDT - 2 months ago

Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 2:09 PM EDT - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB JNJ LLY MRK

Sep 3, 2025, 12:16 PM EDT - 2 months ago

Gilead starts building manufacturing hub under $32 billion planned US investments

Sep 3, 2025, 11:30 AM EDT - 2 months ago

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

Sep 2, 2025, 9:20 AM EDT - 2 months ago

Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales

Aug 26, 2025, 3:03 AM EDT - 2 months ago

EU approves Gilead's new injection for preventing HIV

Aug 26, 2025, 3:00 AM EDT - 2 months ago

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

HedgeAlerts Nov. 16 at 10:22 PM

0 · Reply

Dachshundtrader Nov. 16 at 8:35 AM

$ASMB $GILD

0 · Reply

WayneSmith Nov. 16 at 2:02 AM

$GILD $PANW $PFE $DHR Buy low and sell high

0 · Reply

HedgeAlerts Nov. 15 at 10:25 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 5:07 PM

0 · Reply

TechTraderGrok Nov. 14 at 9:08 PM

0 · Reply

GorillaTrades Nov. 14 at 8:20 PM

Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Frontline $FRO +7.7%, Gilead Sciences $GILD +5.1%, and Steel Dynamics $STLD +2.8%

0 · Reply

HedgeAlerts Nov. 14 at 6:08 PM

0 · Reply

GettnFibbywIT Nov. 14 at 5:03 PM

$GILD $XLV $IBB GILD - Pulled back with broader market, let's see if we can hold below level(s)........

0 · Reply

LiquidThetaOptions Nov. 14 at 4:31 PM

0 · Reply

ZacksResearch Nov. 14 at 1:43 PM

$GILD surges 35.6% YTD — driven by multiple factors including its strong HIV franchise 🚀 🧪 ARTISTRY-1 study hits primary endpoint with promising single-tablet regimen 💊 Biktarvy & Descovy fueling top-line growth ⏩ Yeztugo's strong initial uptake shows potential for growth Discover the full potential of GILD's HIV franchise here 👉 https://www.zacks.com/stock/news/2791096/gilds-investigational-regimen-for-hiv-treatment-meets-primary-goal?cid=sm-stocktwits-2-2791096-body-21104&ADID=SYND_STOCKTWITS_TWEET_2_2791096_BODY_21104

0 · Reply

ZacksResearch Nov. 14 at 12:43 PM

$GILD just delivered a big win in HIV treatment — and the market noticed. Its ARTISTRY-1 investigational combo hit the primary goal, with the once-daily bictegravir/lenacapavir regimen proving non-inferior to more complex setups, giving the stock a boost. Full breakdown here 👉 https://www.zacks.com/stock/news/2791096/gilds-investigational-regimen-for-hiv-treatment-meets-primary-goal?cid=sm-stocktwits-2-2791096-teaser-21102&ADID=SYND_STOCKTWITS_TWEET_2_2791096_TEASER_21102

0 · Reply

GetOverHere_ Nov. 14 at 10:27 AM

Breaking out!? How much volume do you think it takes to gap ARBB up? ARBB has not even 700K shares float and recent news. Hoping for a 100% run on ARBB $CVX $GILD $SPGI $CTAS *

0 · Reply

HedgeAlerts Nov. 14 at 7:28 AM

Hedge Alert Live - Protect Your Portfolio Contract: $GILD $125.00 Put · NOV 21, 2025 Exp Entry Price: $2.21 - $2.31 Exit Price Target: $4.82 Profit Margin: +118% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

macrossluvsrobotech Nov. 14 at 3:06 AM

$LXRX Rotation into Biotech and Pharma out of AI is happening. Don't let them take your shares. $BIB $GILD

0 · Reply

Serranito Nov. 13 at 10:50 PM

$GILD Breakout???

1 · Reply

Swing_Tradr Nov. 13 at 9:23 PM

💎TradrSense Daily Gem 💎 In rocky markets, look to sectors showing resilience, like Energy and Health Care today, as potential safe havens. For swing trading, keep your orders tight and be ready to jump ship if momentum shifts course. 🚤 Always have an exit strategy! $LLY $MRK $GILD $CVX $XOM

0 · Reply

DomLuminous Nov. 13 at 7:57 PM

$GILD looks toppy, if this sells off risk will be back on $SPY

0 · Reply

topstockalerts Nov. 13 at 7:40 PM

Gilead Sciences announced on Thursday positive preliminary results from its Phase 3 ARTISTRY-1 trial for an investigational HIV treatment. The single-tablet daily regimen combining bictegravir and lenacapavir (BIC/LEN) met its primary endpoint of non-inferiority compared with multi-tablet antiretroviral therapies in adults with virologically suppressed HIV. The study assessed the percentage of participants with HIV-1 RNA levels ≥50 copies/mL at Week 48, as defined by the FDA snapshot algorithm. Gilead reported the treatment was generally well tolerated, with no new or significant safety concerns identified. The new BIC/LEN combination could provide a more convenient dosing option for people living with HIV who currently manage complex treatment regimens. At baseline, participants in ARTISTRY-1 were taking between two and eleven HIV pills daily, with about 40% dosing more than once per day. $GILD

0 · Reply

StocktwitsNews Nov. 13 at 7:09 PM

Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV $GILD $JGRO $DUHP https://stocktwits.com/news/equity/markets/gileads-experimental-one-pill-regimen-proved-non-inferior-to-multi-pill-regimens-in-treating-hiv/cLP9XI1REEO

0 · Reply

JarvisFlow Nov. 13 at 6:12 PM

Needham has updated their rating for Gilead Sciences ( $GILD ) to Buy with a price target of 140.

0 · Reply

Johnny_Lever Nov. 13 at 6:08 PM

$GILD

0 · Reply

Market Cap	155.11B
Revenue (ttm)	28.75B
Net Income (ttm)	480.00M
EPS (ttm)	N/A
PE Ratio	15.29
Forward PE	15.31
Profit Margin	1.67%
Debt to Equity Ratio	1.16

Volume	6,599,500
Avg Vol	7,525,106
Day's Range	N/A - N/A
Shares Out	1.24B
Stochastic %K	75%
Beta	0.32
Analysts	Strong Sell
Price Target	$132.88